LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported a net loss attributable to common stockholders of $1.94M for the first quarter of 2026, compared with a net loss of $709.6K in the year-ago quarter. The company remains pre-revenue with no reported revenues in either period; diluted loss per share was $(0.18) in 1Q 2026 versus $(0.29) in 1Q 2025.
Financial Highlights
- Revenue: No revenues reported for 1Q 2026 or 1Q 2025 (company remains pre-revenue).
- Net income: Net loss attributable to common stockholders of $1.94M for 1Q 2026, versus net loss of $709.6K in 1Q 2025.
- Diluted EPS: Loss per common share – basic and diluted of $(0.18) for 1Q 2026, versus $(0.29) in 1Q 2025.
Business Highlights
- Clinical development: LB-100 advanced in multiple early-stage trials (ovarian, colorectal, sarcoma); investigators took actions after two serious adverse events.
- Safety and regulatory: An IRB placed the colorectal study on hold pending review; the Investigator’s Brochure was updated to version 5.0 and distributed.
- Operations and spending: R&D and G&A expenses increased to support trials, oversight activities, recommissioning of the LiGHT system and integration work related to the Liora acquisition.
- Strategy and liquidity: Management is pursuing partnerships, acquisitions and financing alternatives to advance LB-100 and LiGHT capabilities and to sustain operations.
Original SEC Filing: LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ] – 10-Q – May. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.